v3.26.1
Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended
Mar. 28, 2026
Mar. 29, 2025
Income Statement [Abstract]    
Net sales $ 132,089 $ 123,876
Cost of sales (including depreciation and amortization of $10,087 and $10,265, respectively) 41,320 40,820
Gross profit 90,769 83,056
Selling, general and administrative expense 78,325 73,502
Research and development expense 2,467 3,011
Restructuring costs 454 0
Depreciation and amortization 1,107 1,593
Loss on disposals 0 81
Operating income 8,416 4,869
Interest expense, net 4,326 7,509
Other (income) expense (427) 777
Other expense 3,899 8,286
Income (loss) before income taxes 4,517 (3,417)
Income tax expense (benefit), net 571 (95)
Net income (loss) 3,946 (3,322)
(Income) loss attributable to noncontrolling interest (833) 685
Net income (loss) attributable to Bioventus Inc. 3,113 (2,637)
Change in foreign currency translation adjustments (1,468) 633
Change in the fair value of cash flow hedges 1,000 0
Comprehensive income (loss) 3,478 (2,689)
Comprehensive (income) loss attributable to noncontrolling interest (744) 563
Comprehensive income (loss) attributable to Bioventus Inc. $ 2,734 $ (2,126)
Income (loss) per share of Class A common stock:    
Income (loss) per share of Class A common stock:, basic (in dollars per share) $ 0.05 $ (0.04)
Income (loss) per share of Class A common stock:, diluted (in dollars per share) $ 0.04 $ (0.04)
Weighted-average shares of Class A common stock outstanding    
Basic (in shares) 67,296,336 66,008,683
Diluted (in shares) 70,008,291 66,008,683